Cited 0 times in
항암화학요법에 의하여 골수억제가 수반된 진행암 환자에서 Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor(rhGM-CSF,LBD-005)의 제3상 임상연구;rhGM-CSF의 백혈구 감소증에 대한 효과
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김주항 | - |
dc.contributor.author | 라선영 | - |
dc.contributor.author | 유내춘 | - |
dc.contributor.author | 정현철 | - |
dc.contributor.author | 조재용 | - |
dc.date.accessioned | 2021-12-27T17:02:21Z | - |
dc.date.available | 2021-12-27T17:02:21Z | - |
dc.date.issued | 1995-01 | - |
dc.identifier.issn | 0496-6872 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/186339 | - |
dc.description.abstract | Background: Recombinant human granulocyte-macrophage colony stimulating factor(rhGM- CSF, LBD-005) may reduce chemotherapy induced myelosuppression, and thus reduce the incidence of neutropenic fever and infection after the dose intensive chemotherapy. In previous phase I and II studies, clinical efficacies and side effects of rhGM-CSF were evaluated, and the dose of 250ug/m(2)/day for 10 consecutive days subcutaneous administration was recommended for the further clinical triaL Methods: In this phase III trial, we evaluated the efficacy and safety of rhGM-CSF in 35 advanced cancer pstients after combination chemotherapy. Every eligible patients received at least 2 cycles of chemotherapy with the same dose and schedule. At the first cycle, control period, scheduled chemotherapy was given without rhGM-CSF, and at the second cycle, treatment period, rhGM-CSF was administered for 10 consecutive days subcutaneously with the dose of 250u/m(2)/day after the same chemotherapy given previously. During observation and treatment period, clinical and pathoiogical effects were monitered. Resnlta: All enrolled 35 patients were evaluable, and 14 patients(40%) had stomach cancer. The hematologic parameters were compared between two periods; mean nadir of WBC(neutrophil) counts during the control period and treatment period were 1,154+-485/mm(3)(241/mm(3)+ 242) and 2,486+1,554/mm(3)(912+-1,186/mm(3)) respectively(P<0.0001). Also the recovery time of neutropenia was shortened(P<0.0001). Incidence of infection and the necessities of antibiotics administration were decreased(days of antibiotics adminiatration: 7 days during control period and 10 days during treatment period). Most petients showed mild, talerable toxicities like chest tightness and general malaise, except 2 patients with the reduced dose of 150 ug/m(2)/day due to grade II toxicities of chest tightness and abdominal pain. Conclnsion: Above results suggested that the administration of rhGM-CSF after chemotherapy can reduce the degree of neutropenia and the side effects of rhGM-CSF were acceptable. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | Korean | - |
dc.publisher | 대한암학회 | - |
dc.relation.isPartOf | Journal of the Korean Cancer Association(대한암학회지) | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | 항암화학요법에 의하여 골수억제가 수반된 진행암 환자에서 Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor(rhGM-CSF,LBD-005)의 제3상 임상연구;rhGM-CSF의 백혈구 감소증에 대한 효과 | - |
dc.title.alternative | A Phase III Clinical Trial of Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor(rhGM-CSF, LBD-005) in Cancer Patients with Chemotherapy-induced Myelosuppression | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | 이경희 | - |
dc.contributor.googleauthor | 라선영 | - |
dc.contributor.googleauthor | 노재경 | - |
dc.contributor.googleauthor | 이종인 | - |
dc.contributor.googleauthor | 이혜란 | - |
dc.contributor.googleauthor | 박준오 | - |
dc.contributor.googleauthor | 조재용 | - |
dc.contributor.googleauthor | 정현철 | - |
dc.contributor.googleauthor | 김주항 | - |
dc.contributor.localId | A00945 | - |
dc.contributor.localId | A01316 | - |
dc.contributor.localId | A02457 | - |
dc.contributor.localId | A03773 | - |
dc.contributor.localId | A03899 | - |
dc.relation.journalcode | J01813 | - |
dc.subject.keyword | rhGM-CSF | - |
dc.subject.keyword | Cancer patients | - |
dc.subject.keyword | Combinetion chemotherapy | - |
dc.subject.keyword | Myelosuppression | - |
dc.contributor.alternativeName | Kim, Joo Hang | - |
dc.contributor.affiliatedAuthor | 김주항 | - |
dc.contributor.affiliatedAuthor | 라선영 | - |
dc.contributor.affiliatedAuthor | 유내춘 | - |
dc.contributor.affiliatedAuthor | 정현철 | - |
dc.contributor.affiliatedAuthor | 조재용 | - |
dc.citation.volume | 27 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 804 | - |
dc.citation.endPage | 815 | - |
dc.identifier.bibliographicCitation | Journal of the Korean Cancer Association (대한암학회지), Vol.27(5) : 804-815, 1995-01 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.